Liquidity & Technical
Liquidity & Technical
MICC began trading on 8 December 2025 as a Unilever spin-off, so the tape is only six months old — long-trend anchors (SMA 200, 1-year return, multi-year relative strength) do not yet exist. Reported ADV of roughly €21M against a €9.9B market cap puts the name in the capacity-constrained bucket for institutions: tradable for sub-€500M funds at a 5% weight, but a binding constraint above that. The post-spin tape itself reads neutral — a -34% drawdown from a €19.87 February peak to a €13.04 April low has been retraced 45%, momentum has flipped positive on the short MAs, and realized vol has compressed from a 75% spike to roughly 48% — but with no SMA 200 yet to anchor regime, conviction should stay measured.
1 — Portfolio implementation verdict
5-day capacity at 20% ADV (€)
Largest 5-day position (% mcap)
Supported AUM, 5% weight (€)
ADV 20d / Mcap (%)
Technical stance (-3 to +3)
The data pipeline flags MICC as "Illiquid / specialist only" under its standard institutional threshold (largest 5-day clearable position under 0.5% of market cap). In practical terms: a fund up to roughly €430M can build a full 5% MICC position within five trading days at 20% ADV participation, and a fund up to roughly €1.08B can build a 2% position. Above those thresholds, sizing requires patient, multi-week block execution. Liquidity is the binding portfolio constraint, not the tape.
2 — Price snapshot
Last close (€)
YTD return (%)
Since-IPO return (%)
52-week position (0–100)
Realized vol 30d (%)
Beta and 1-year return are unavailable — the trading history is too short to compute either with statistical meaning. Use these placeholders rather than fabricating long-history risk metrics.
3 — The critical chart: price + moving averages
Price is above both moving averages today. SMA 200 is not yet computable (would require 200 trading sessions; we have 120), so call this a young uptrend off the April low rather than a regime read. The most recent regime signal is a short-term golden cross of SMA 20 above SMA 50 on 2026-05-20, which followed an earlier death cross on 2026-03-09 — the bounce off €13.07 (-34% peak-to-trough) has now traced back to mid-range.
SMA 20 crossed back above SMA 50 on 2026-05-20. This is the short-MA regime flip — the long-MA flip (50 vs 200) cannot yet be assessed.
4 — Relative strength
Relative-strength benchmarks are not populated in the data pipeline for this ticker. The expected SPY (broad-market) and sector-ETF series are empty; a peer basket is not constructed for this name. Without a benchmark we cannot answer whether outperformance versus the European staples complex is widening or narrowing. This is a real gap — a follow-up query should rebase MICC against EXSA (Euro STOXX 600 Food, Beverage & Tobacco), the SPDR XLP (US staples), and Unilever (parent) since 8 December 2025, because relative strength versus the spun-off parent is the most diagnostic test of whether the market is rewarding the standalone story.
5 — Momentum: RSI and MACD
Momentum is positive but losing thrust. RSI sits at 57.9 — clearly above the March/April trough zone (low 30s) but well off the overbought spike of 75.2 that printed at the February top. The MACD histogram flipped green on 2026-04-30 (the +14% gap-up day off the lows), peaked around 0.25 in early May, and has been narrowing for two weeks. Read it together: the bounce is real, but the impulse phase is over. Near-term action is more likely a sideways digestion between €15 and €17 than a vertical extension toward the February high.
6 — Volume, volatility, and sponsorship
The catalyst column is intentionally blank — neither the web-research nor news pipeline has captured a confirmed news driver for these dates, and speculating in their absence would erode credibility. The diagnostic pattern is clear without it: the two largest volume spikes (Apr 30 and May 15) were both up-days, while the largest down-day on record (Feb 12, -17.9% gap-down from the €19.87 peak) printed on lower-multiple volume — that is, buying conviction has been bigger than selling conviction since the April low. Whether the move is sustainable depends on whether those upside volume signatures repeat over the next two to four weeks; one more 5x volume up-day would meaningfully strengthen the bullish read.
Realized vol traced a textbook stress-then-mean-reversion arc: a 75% peak (above the p80 stress band) through February–March as the Feb 12 gap-down was absorbed, a sharp compression into the 20s by mid-May (below the p20 calm band), and a renewed pickup into the late-50s as the volume spikes of late April / mid-May worked through the 30-day window. Current 48% sits exactly at the historical median — the tape is digesting, not signaling. Above 65% would mark renewed stress; persistent sub-30% would be the all-clear.
7 — Institutional liquidity panel
This name is sized for institutional readers, not retail. The question is not whether you can buy 1,000 shares — it is what fund AUM and position weight clear in a normal five-day execution window.
The pipeline classification is "Illiquid / specialist only" because the largest position that clears in five days at 20% ADV is under 0.5% of market cap. This is a strict definition. For mid-sized funds the practical read is softer — the name is capacity-constrained, tradable size-aware, not unusable.
ADV and turnover
ADV 20d (shares)
ADV 20d (€ value)
ADV 60d (shares)
ADV 20d / Mcap (%)
Annual turnover (%)
The 35.5% annualized turnover is below the 60–100% range typical of seasoned mid-cap staples — characteristic of a post-spin float where Unilever shareholders are still settling into their new holding and ~19.85% remains stranded in Unilever's residual stake.
Fund-capacity table — what AUM can run this position?
Read the row that matches your house participation policy. A patient desk at 10% ADV supports a 5% weight for a fund up to roughly €216M, and a 2% weight up to €541M. A more active desk at 20% ADV doubles those thresholds. Above €1B in AUM, MICC is a fractional-percent position or a multi-week scaled build.
Liquidation runway — how long to exit?
A 1% issuer-level position requires 23 trading sessions to exit at 20% ADV participation — roughly five weeks of patient selling, with all the price-impact and information-leakage risk that implies. A 2% position effectively takes a quarter. The honest read: this stock cannot absorb hedge-fund-scale concentration; sizing decisions need to assume a multi-week unwind even on a panic exit.
The 60-day median intraday range is 0.91% — narrow, which on its own would suggest low impact cost — but with ADV at just 0.21% of market cap, that comfortable range is a function of light flow, not depth. Large orders will widen it.
8 — Technical scorecard + stance
Stance: neutral on a 3–6 month horizon, with a mildly constructive lean off the April low. The tape has retraced 24% off €13.07, the short MAs have flipped bullish, and volume conviction has tilted to the buy side — but the realized-vol re-acceleration from 21% to 48% in two weeks suggests the digestion phase is not over, and without an SMA 200 anchor there is no defensible long-trend read. Levels to watch: a sustained close above €17.00 (the May 15 intraday high and the post-gap supply zone) would confirm the bullish reclaim and put €18–19 back in scope; a break below €14.00 (the SMA 50 / Bollinger lower / prior consolidation floor) would invalidate the bounce and re-open the €13 lows. Between those two posts, this is a sit-and-watch.
Liquidity is the constraint, not the tape. For funds above roughly €430M targeting a 5% weight, the correct action is build slowly over multiple weeks — not avoid, but not size-up either. Smaller funds can act on the technical setup without liquidity friction; larger funds should treat the post-spin float as a multi-week accumulation problem regardless of which level breaks first.